Type-2 DiabetesNCT00478127
Hepatocyte Growth Factor and Cardiovascular Autonomic Function
An observational study of Type-2 Diabetes, run by Oita Red Cross Hospital.
Trial summary
In this study, we tested the hypothesis that elevated HGF is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients not receiving insulin treatment. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Type-2 Diabetes
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Who may be able to join
- Type-2 diabetes
Who cannot join
- Type-1 diabetes
About this study
In this study, we tested the hypothesis that elevated HGF is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients not receiving insulin treatment.
- Conditions
- Type-2 Diabetes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 May 2007 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type-2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Other
Sponsor and investigators
- Lead sponsor
- Oita Red Cross Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Futoshi Anan, Principal investigator, Oita Red Cross Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00478127
- Sponsor's protocol ID
- AO-272
- Status last verified
- May 2007
- First submitted
- 23 May 2007
- Last updated
- 24 May 2007
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 May 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hepatocyte Growth Factor and Cardiovascular Autonomic Function
- ClinicalTrials.gov ID
- NCT00478127
- Acronym / sponsor ID
- AO-272
- Conditions
- Type-2 Diabetes
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- Oita Red Cross HospitalUniversity, hospital or other
- First posted
- 24 May 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study, we tested the hypothesis that elevated HGF is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients not receiving insulin treatment.
Study design
- Time perspective
- Other
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Type-2 diabetes
Key exclusion criteria (1 listed)
- Type-1 diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 May 2007.
Related trials for Type-2 Diabetes
Not yet recruiting
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Active, not recruiting
Helping Adults With Type 2 Diabetes Use Their Health Data for Healthy Diabetes Self-Management
Type 2 Diabetes Mellitus (T2DM)
Not yet recruiting
Care COMPASS Study
Diabetes Mellitus ( Type 1 and Type 2), Hypertension
Enrolling by invitationObservational study
Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis
Type 2 Diabetes
RecruitingObservational study
Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity
Sarcopenia, Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Futoshi Anan principal investigator
Oita Red Cross Hospital
Questions about this trial
What is this clinical trial studying?
An observational study of Type-2 Diabetes, run by Oita Red Cross Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 May 2007. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 May 2007.